Isolation of CD4+CD25+ regulatory T cells for clinical trials
Isolation of CD4+CD25+ regulatory T cells for clinical trials
复制标题
DOI：
10.1016/j.bbmt.2006.01.005
复制
发表时间：
2006-03-01
影响因子：
4.3
通讯作者：
Edinger, M
中科院分区：
文献类型：
--
作者：
Hoffmann, P;Boeld, TJ;Edinger, M
在小鼠疾病模型中，供体CD4(+)CD25（+）调节性T细胞的过继性转移已被证明可防止同种异体骨髓移植后的致命移植物抗宿主病。符合良好生产规范（GMP）指南的高效分离策略是人类CD4(+)CD25（+）调节因子T细胞临床应用的先决条件。在这里，我们描述了使用GMP条件下的两步磁性细胞分离方案从标准白细胞分离产品中分离出具有调节功能的CD4(+)CD25(+) T细胞。生成的细胞产物平均含有49.5%的CD4(+)CD25（高）T细胞，在表型和功能上代表天然CD4(+)CD25（+）调节性T细胞，并显示出与非gmp批准的荧光激活细胞分选纯化的CD4(+)CD25（+）调节性T细胞制剂相当的抑制活性。(C) 2006年美国血液和骨髓移植学会。
The adoptive transfer of donor CD4(+)CD25(+) regulatory T cells has been shown to protect from lethal graft-versus-host disease after allogeneic bone marrow transplantation in murine disease models. Efficient isolation strategies that comply with good manufacturing practice (GMP) guidelines are prerequisites for the clinical application of human CD4(+)CD25(+) regulators, T cells. Here we describe the isolation of CD4(+)CD25(+) T cells with regulatory function from standard leukapheresis products by using a 2-step magnetic cell-separation protocol performed under GMP conditions. The generated cell products contained on average 49.5% CD4(+)CD25(high) T cells that phenotypically and functionally represented natural CD4(+)CD25(+) regulatory T cells and showed a suppressive activity comparable to that of CD4(+)CD25(+) regulatory T-cell preparations purified by non-GMP-approved fluorescence-activated cell sorting. (C) 2006 American Society for Blood and Marrow Transplantation.